Trials / Completed
CompletedNCT05268068
A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China
A Phase 1 Study in Healthy Chinese Subjects to Assess the Pharmacokinetics, Safety and Tolerability After a Single Dose of Risankizumab
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study to assess the pharmacokinetics, safety, tolerability and immunogenicity following a single subcutaneous (SC) or intravenous (IV) dose of risankizumab in healthy Chinese participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Risankizumab | Intravenous (IV) Infusion |
| DRUG | Risankizumab | Subcutaneous (SC) Injection |
Timeline
- Start date
- 2019-06-27
- Primary completion
- 2020-04-26
- Completion
- 2020-04-26
- First posted
- 2022-03-07
- Last updated
- 2022-03-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05268068. Inclusion in this directory is not an endorsement.